The AP-GELP Study: A Clinical Trial on the Effects of Apremilast in Female Genital Erosive Lichen Planus

Inclusion Criteria: * Moderate to severe GELP at inclusion with the diagnosis based on characteristic clinical and/or histological features. Minimum GELP score 5/30 in vagina and/or vulva (scored separately), of which erythema and pain ≥1 are mandatory * Informed consent from the patient to the protocol and clinical procedures. Exclusion Criteria: * Patients receiving other systemic immune modulating therapy * Concomitant use of strong CYP3A4 enzyme inducers * Inadequate birth control, pregnancy and/or breast-feeding * Depression and suicidal ideation * Patients with severe renal impairment * Patients with active tuberculosis, serious infections or cancer * Unexplained and clinically significant weight loss in underweight patients * Hypersensitivity to the active substance(s) or to any of the excipients * Hereditary problems of galactose intolerance, lactase deficiency or glucose-galactose malabsorption * Participating in another trial that might affect the current study or there should be minimum 90 days between participation in another intervention trial